Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

著者: F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi, Xiang Hu, Xiandong Lin, Qilong Zhang, J. Feng, Yi Ba, Yanshi Liu, W. Li, Yongqian Shu, Yi Jiang, Quan Li, J.W. Wang, H. T. Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu - Annals of Oncology 2019 被引用: 476